#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	6730	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2075	620.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1387	1387	C	826	C,A	534,3	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	6730	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2075	620.9	0	HET	.	.	.	A69G	.	69	69	A	272	272	A	669	A,G	243,195	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12326	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3894	599.8	0	.	n	.	0	T695C	SNP	695	695	T	1068	1068	C	813	C,A,T	514,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12326	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3894	599.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1710	1710	A	697	A	473	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12326	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3894	599.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2344	2344	C	682	C,T,A,G	450,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12326	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3894	599.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2418	2418	A	680	A	446	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12326	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3894	599.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2970	2970	C	810	C	537	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	494	folP	855	855	100.0	folP.l15.c4.ctg.1	1611	60.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1079	1081	AGC	90;90;91	A;G;C	60;59;61	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1556	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3599	84.4	1	SNP	p	S91F	1	.	.	271	273	TTC	677	679	TTC	134;134;134	T;T;C,A	87;87;86,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1556	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3599	84.4	1	SNP	p	D95G	1	.	.	283	285	GGC	689	691	GGC	141;143;143	G;G;C	92;94;92	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1556	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3599	84.4	1	SNP	p	G95N	0	.	.	283	285	GGC	689	691	GGC	141;143;143	G;G;C	92;94;92	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	438	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1555	58.3	1	SNP	p	G45D	0	.	.	133	135	GGC	508	510	GGC	145;145;145	G;G;C	92;96;97	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	328	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1039	61.6	0	.	n	.	0	A197.	DEL	197	197	A	714	714	A	133	A	92	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1230	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3115	76.9	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	100;100;105	G,C;A;C	69,1;63;70	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1230	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3115	76.9	1	SNP	p	R87I	0	.	.	259	261	CGT	581	583	CGT	104;103;103	C;G;T	72;65;69	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1230	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3115	76.9	1	SNP	p	R87W	0	.	.	259	261	CGT	581	583	CGT	104;103;103	C;G;T	72;65;69	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1230	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3115	76.9	1	SNP	p	S87R	1	.	.	259	261	CGT	581	583	CGT	104;103;103	C;G;T	72;65;69	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1230	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3115	76.9	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	104;104;104	T;C;C	69;71;70	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1080	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2842	73.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1771	1773	GGC	75;75;76	G;G,C;C,T,G	50;51,1;53,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1446	1448	GCA	145;147;148	G;C;A	97;98;99	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1449	1451	ATC	151;151;152	A;T;C	99;100;100	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1461	1463	GTG	151;152;150	G;T;G	103;102;103	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1461	1463	GTG	151;152;150	G;T;G	103;102;103	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1965	1967	ACC	77;77;77	A;C;C,A	49;53;54,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2019	2021	GCG	62;62;63	G;C;G	45;46;46	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2019	2021	GCG	62;62;63	G;C;G	45;46;46	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2142	2144	AGC	72;72;75	A;G,C,A;C	47;46,1,1;51	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2151	2153	GGC	68;69;67	G,C;G;C,G	44,1;46;42,1	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1156	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2468	88.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2169	2171	CCG	69;69;69	C,G,A;C;G,T,C	39,2,1;42;42,1,2	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2000	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3541	103.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1788	1790	CCG	101;102;104	C;C;G,C	59;64;59,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	664	porA	1146	1146	99.91	porA.l6.c30.ctg.1	2027	62.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	617	617	C	61	C	37	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	782	porB1b	1035	1035	98.66	porB1b.l6.c17.ctg.1	1723	83.8	0	.	p	.	0	E48K	NONSYN	142	144	GAA	518	520	AAA	119;121;123	A;A;A	77;77;78	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	782	porB1b	1035	1035	98.66	porB1b.l6.c17.ctg.1	1723	83.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1007	1007	T	90	T	62	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	782	porB1b	1035	1035	98.66	porB1b.l6.c17.ctg.1	1723	83.8	1	SNP	p	G120K	0	.	.	358	360	GGT	734	736	GGT	93;94;92	G;G;T,C	63;65;59,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	782	porB1b	1035	1035	98.66	porB1b.l6.c17.ctg.1	1723	83.8	1	SNP	p	A121D	0	.	.	361	363	GCC	737	739	GCC	97;96;96	G;C;C	62;66;66	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	782	porB1b	1035	1035	98.66	porB1b.l6.c17.ctg.1	1723	83.8	1	SNP	p	A121N	0	.	.	361	363	GCC	737	739	GCC	97;96;96	G;C;C	62;66;66	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2860	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4971	110.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	268	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1093	51.8	1	SNP	p	V57M	1	.	.	169	171	ATG	499	501	ATG	112;109;110	A;T;G	69;68;69	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
